Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ATORVASTATIN Cause Product substitution issue? 424 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 424 reports of Product substitution issue have been filed in association with ATORVASTATIN (Atorvastatin calcium). This represents 0.5% of all adverse event reports for ATORVASTATIN.

424
Reports of Product substitution issue with ATORVASTATIN
0.5%
of all ATORVASTATIN reports
0
Deaths
36
Hospitalizations

How Dangerous Is Product substitution issue From ATORVASTATIN?

Of the 424 reports, 36 (8.5%) required hospitalization, and 7 (1.7%) were considered life-threatening.

Is Product substitution issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ATORVASTATIN. However, 424 reports have been filed with the FAERS database.

What Other Side Effects Does ATORVASTATIN Cause?

Type 2 diabetes mellitus (7,556) Myalgia (7,155) Drug hypersensitivity (3,929) Drug ineffective (3,865) Fatigue (3,439) Arthralgia (3,338) Rhabdomyolysis (3,286) Dyspnoea (3,137) Nausea (2,888) Asthenia (2,791)

What Other Drugs Cause Product substitution issue?

AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (2,832) BUPROPION (1,578) METHYLPHENIDATE (1,408) CLONAZEPAM (1,288) LAMOTRIGINE (979) ALBUTEROL (864) LEVOTHYROXINE (803) DULOXETINE (766) ESTRADIOL (692) SERTRALINE (636)

Which ATORVASTATIN Alternatives Have Lower Product substitution issue Risk?

ATORVASTATIN vs ATORVASTATIN\EZETIMIBE ATORVASTATIN vs ATOSIBAN ATORVASTATIN vs ATOVAQUONE ATORVASTATIN vs ATOVAQUONE\PROGUANIL ATORVASTATIN vs ATRACURIUM

Related Pages

ATORVASTATIN Full Profile All Product substitution issue Reports All Drugs Causing Product substitution issue ATORVASTATIN Demographics